MoonLake Immunotherapeutics
MLTX10.630USD
+0.340+3.30%
終値 11/07, 16:00（ET）15分遅れの株価
677.18M時価総額
損失額直近12ヶ月PER
詳細情報 MoonLake Immunotherapeutics 企業名
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
MoonLake Immunotherapeuticsの企業情報
企業コードMLTX
会社名MoonLake Immunotherapeutics
上場日Oct 20, 2020
最高経営責任者「CEO」Dr. Jorge Santos Da Silva
従業員数100
証券種類Ordinary Share
決算期末Oct 20
本社所在地Dorfstrasse 29
都市ZUG
証券取引所NASDAQ Capital Market Consolidated
国Switzerland
郵便番号6300
電話番号41415108022
ウェブサイトhttps://moonlaketx.com/
企業コードMLTX
上場日Oct 20, 2020
最高経営責任者「CEO」Dr. Jorge Santos Da Silva
MoonLake Immunotherapeuticsの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.13M
+1.59%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.13M
+1.59%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Tue, Nov 4
更新時刻: Tue, Nov 4
株主統計
種類
株主統計
株主統計
比率
BVF Partners L.P.
27.67%
Fidelity Management & Research Company LLC
7.44%
Avoro Capital Advisors LLC
5.81%
Reich (Kristian)
4.38%
Santos da Silva (Jorge)
4.31%
他の
50.37%
株主統計
株主統計
比率
BVF Partners L.P.
27.67%
Fidelity Management & Research Company LLC
7.44%
Avoro Capital Advisors LLC
5.81%
Reich (Kristian)
4.38%
Santos da Silva (Jorge)
4.31%
他の
50.37%
種類
株主統計
比率
Hedge Fund
41.51%
Investment Advisor
20.11%
Investment Advisor/Hedge Fund
17.19%
Individual Investor
11.03%
Research Firm
2.11%
Venture Capital
1.30%
Bank and Trust
0.07%
Pension Fund
0.05%
他の
6.62%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
336
52.26M
73.22%
-13.87M
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
2023Q2
175
60.28M
100.54%
+9.44M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BVF Partners L.P.
19.75M
31.1%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.31M
8.36%
-114.00K
-2.10%
Jun 30, 2025
Avoro Capital Advisors LLC
4.15M
6.54%
+1.38M
+49.81%
Jun 30, 2025
Reich (Kristian)
3.13M
4.93%
+48.98K
+1.59%
Sep 02, 2025
Santos da Silva (Jorge)
3.08M
4.85%
--
--
Mar 15, 2025
T. Rowe Price Associates, Inc.
2.61M
4.12%
-360.60K
-12.13%
Jun 30, 2025
Cormorant Asset Management, LP
1.99M
3.14%
-6.50M
-76.52%
Sep 30, 2025
Citadel Advisors LLC
1.67M
2.64%
+195.41K
+13.22%
Jun 30, 2025
Westfield Capital Management Company, L.P.
1.26M
1.98%
-175.39K
-12.22%
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.26M
1.98%
-19.32K
-1.52%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
ALPS Medical Breakthroughs ETF
0.27%
Global X Guru Index ETF
0.16%
Goldman Sachs Future Health Care Equity ETF
0.12%
Virtus LifeSci Biotech Clinical Trials ETF
0.12%
JPMorgan Healthcare Leaders ETF
0.03%
First Trust IPOX Europe Equity Opportunities ETF
0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.01%
John Hancock Multifactor Small Cap ETF
0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
0.01%
Fidelity Blue Chip Growth ETF
0.01%
詳細を見る
ALPS Medical Breakthroughs ETF
比率0.27%
Global X Guru Index ETF
比率0.16%
Goldman Sachs Future Health Care Equity ETF
比率0.12%
Virtus LifeSci Biotech Clinical Trials ETF
比率0.12%
JPMorgan Healthcare Leaders ETF
比率0.03%
First Trust IPOX Europe Equity Opportunities ETF
比率0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
比率0.01%
John Hancock Multifactor Small Cap ETF
比率0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
比率0.01%
Fidelity Blue Chip Growth ETF
比率0.01%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
